Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2013
Event: Entry into a Material Definitive Agreement regarding a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key figures include:
- Shares Issued: 13,750,000 shares of common stock.
- Offering Price: $2.40 per share.
- Underwriter Purchase Price: $2.232 per share.
- Expected Net Proceeds: Approximately $30.4 million (after underwriting discounts, commissions, and estimated offering expenses).
- Expected Closing Date: On or about September 30, 2013.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the execution of an underwriting agreement with Stifel, Nicolaus & Company, Incorporated. This agreement facilitates the issuance of new equity, which will increase the company's cash position upon closing and result in the dilution of existing shareholders.
Guidance, Outlook, and Risks
Management Commentary: The company announced the pricing of the offering via a press release attached as Exhibit 99.1. The offering is made pursuant to a shelf registration statement (Form S-3) filed in January 2013 and declared effective in February 2013.
Risks and Contingencies: The closing of the offering is subject to customary closing conditions. The Underwriting Agreement includes standard representations, warranties, covenants, and indemnification obligations for liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected September 30, 2013).
- Confirm the actual net proceeds received after all expenses are finalized.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and covenants.
- Check subsequent filings for the updated share count and capitalization table post-offering.
- Assess the intended use of the $30.4 million in proceeds as detailed in the prospectus referenced in the filing.